On Nov 21, 2017, Hansoh’s Xintai (Bortezomib for Injection) (available in 1mg and 3.5mg) has received NDA approval from National Medical Products Administration as the first-to-market generic of bortezomib in China.

Bortezomib is a proteasome inhibitor and is an innovative oncology drug for targeted therapy. It is mainly indicated for the treatment of multiple myeloma and mantle cell lymphoma.